ClinicalTrials.gg
CompletedNCT01483963Updated Oct 5, 2017Results posted

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

A Phase 2 interventional study of AA4500 0.29 mg/1 mL and AA4500 0.58 mg/2 mL in Adhesive Capsulitis and Frozen Shoulder, sponsored by Endo Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Bursitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Bursitis · United States.

Enrollment
19th of 41
50 · median 40
Started
2011
with 1 other
Phase 2
6 of 45
none open now
Registered
14th of 45
by date
Lead sponsor
4 of 45
Endo Pharmaceuticals

Among the 45 studies in Bursitis with a site in United States, this one is the 19th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2011, is one of 6 in phase 2, and was the 14th registered.

Bursitis

383 studies on the registry are indexed under Bursitis; 111 are open to participants now.

Browse Bursitis studies →

Open to participants now

4 of the 45 studies in Bursitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 64 Bursitis studies recruiting now, 17 (27%) set no upper age limit and 40 (63%) stop at 75 or younger; none take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Bursitis with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.

Read the detailed description

This study is a Phase 2a, open-label, dose-ranging study of the safety and effectiveness of AA4500 for the treatment of adhesive capsulitis of the shoulder. To be eligible for treatment, a subject must have unilateral idiopathic adhesive capsulitis of the shoulder with restricted range of motion in the affected shoulder for at least 3 months but not more than 12 months. Subjects will be screened for study eligibility within 30 days before injection of study drug.

Approximately 50 adult women and men are to be enrolled in this study. Following screening and determination of study eligibility, Assignment to Cohorts 1-4 is sequential. Subjects assigned to Cohorts 1 through 4 may receive up to 3 injections of AA4500 according to cohort assignment. Each injection will be separated by a minimum of 21 days. Subjects assigned to Cohort 5 will receive home shoulder exercises only, while subjects assigned to Cohorts 1-4 will receive AA4500 and home shoulder exercises. Subjects in Cohort 5 will be offered physical therapy sessions for a period of 2 months following completion of the study.

Dosing will range from 0.29 mg to 0.58 mg with varying volumes.

03

Conditions studied

  • Adhesive Capsulitis
  • Frozen Shoulder

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a male or female and be greater than or equal to 18 years of age
  2. If a female of , have a negative urine pregnancy test and be using an effective method (ie, abstinence, intrauterine device (IUD), hormonal (estrogen/progestin) contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for one menstrual cycle following end of study, or be surgically sterile
  3. Have unilateral idiopathic adhesive capsulitis of one shoulder for at least 3 months but not more than 12 months before the screening visit and be in Stage 2 (frozen or adhesive stage), as determined by the investigator
  4. Have normal range of motion in the contralateral shoulder, as determined by the investigator
  5. Have restricted active range of motion (AROM) in the affected shoulder defined as: a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in AROM in at least one of the following planes as compared with the contralateral shoulder:

    • Forward flexion
    • Abduction
    • External rotation with the elbow up to 90 degrees abduction
    • Internal rotation with the elbow up to 90 degrees abduction
  6. Voluntarily sign and date an agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution.
  7. Be able to complete and understand the various rating instruments in English.

Exclusion criteria

Exclusion Criteria:

  1. Is a pregnant or lactating female or female intending to become pregnant during the study
  2. Is a male who intends to father a child during the study
  3. Has received treatment for adhesive capsulitis or is planning to receive treatment for adhesive capsulitis at any time during the study including but not limited to:

    • physical therapy or acupuncture within 2 weeks before the first injection of AA4500
    • intra-articular or intrabursal injection(s) of lidocaine; suprascapular nerve blocks; ; electroanalgesic and/or thermoanalgesic modalities within 1 month before the screening visit
    • intra-articular or intrabursal injection(s) of sodium hyaluronate within 3 months before the screening visit
    • glenohumeral distension arthrography and/or surgical intervention (including shoulder manipulation under anesthesia) at any time
  4. Has any of the following conditions, as determined by the investigator:

    • Adhesive capsulitis as a result of traumatic injury
    • Pain in the affected shoulder at rest that is greater than or equal to 4 on the 11-point pain scale
    • Active subacromial impingement in the affected shoulder
    • Calcified tendonitis in the affected shoulder
    • Glenohumeral joint arthritis in the affected shoulder
    • Arthrosis of the affected shoulder
    • Chondrolysis of the affected shoulder
    • Subscapularis tendon rupture of the affected shoulder
    • Other rotator cuff injuries of the affected shoulder
    • Uncontrolled hypertension
    • Uncontrolled diabetes
    • Uncontrolled thyroid disease
    • History of thrombosis or post-thrombosis syndrome
    • Physical impairment that would preclude performing the protocol defined exercises
    • Active infection in area to be treated
    • neurological disease
    • Coagulation disorder, using anticoagulant (except for less than or equal to 150 mg aspirin) within 7 days prior to each injection day
    • Known active or C (history of hepatitis A permitted)
    • Other significant medical condition (eg, morbid obesity, cervical disc disease), which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  5. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits.
  6. Has received oral or intravenous steroids for any reason within 3 weeks before the screening visit
  7. Has received an drug or treatment within 30 days before the first dose of study drug.
  8. Has a known systemic allergy to collagenase or any other of AA4500 or any other procedural medication.
  9. Has, at any time, received collagenase for the treatment of adhesive capsulitis.
  10. Is unable to undergo an x-ray or MRI () evaluation of the affected shoulder.
  11. Is planning to be treated with commercial Xiaflex at any time during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    AA4500 0.29 mg/1 mL

    Up to three injections

    Biological: AA4500 0.29 mg/1 mL · Other: Shoulder exercises

  • Experimental
    AA4500 0.58 mg/2 mL

    Up to three injections

    Biological: AA4500 0.58 mg/2 mL · Other: Shoulder exercises

  • Experimental
    AA4500 0.58 mg/1 mL

    Up to three injections

    Biological: AA4500 0.58 mg/1 mL · Other: Shoulder exercises

  • Experimental
    AA4500 0.58 mg/0.5 mL

    Up to three injections

    Biological: AA4500 0.58 mg/0.5 mL · Other: Shoulder exercises

  • Other
    Shoulder exercises

    Home shoulder exercises for 64 days

    Other: Shoulder exercises

Interventions

  • BiologicalAA4500 0.29 mg/1 mL

    Drug page: Microbial Collagenase

    treatment of adhesive capsulitis

    Also known as: collagenase clostridium histolyticum, XIAFLEX, XIAPEX

  • BiologicalAA4500 0.58 mg/2 mL

    Drug page: Microbial Collagenase

    treatment of adhesive capsulitis

    Also known as: collagenase clostridium histolyticum, XIAFLEX, XIAPEX

  • BiologicalAA4500 0.58 mg/1 mL

    Drug page: Microbial Collagenase

    treatment of adhesive capsulitis

    Also known as: collagenase clostridium histolyticum, XIAFLEX, XIAPEX

  • BiologicalAA4500 0.58 mg/0.5 mL

    Drug page: Microbial Collagenase

    treatment of adhesive capsulitis

    Also known as: collagenase clostridium histolyticum, XIAFLEX, XIAPEX

  • OtherShoulder exercises

    Home shoulder exercises, minimum of 3 times per day

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 92 in Active Forward Flexion

    Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder

    Time frame: Baseline, Day 92

Secondary outcomes

  1. Change From Baseline to Day 92 in Passive Forward Flexion

    Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder

    Time frame: Baseline, Day 92

  2. Change From Baseline to Day 92 in Active Abduction

    AROM measurement using a goniometer to assess abduction in the affected shoulder

    Time frame: Baseline, Day 92

  3. Change From Baseline to Day 92 in Passive Abduction

    PROM measurement using a goniometer to assess abduction in the affected shoulder

    Time frame: Baseline, Day 92

  4. Change From Baseline to Day 92 in Active External Rotation

    AROM measurement using a goniometer to assess external rotation in the affected shoulder

    Time frame: Baseline, Day 92

  5. Change From Baseline to Day 92 in Passive External Rotation

    PROM measurement using a goniometer to assess external rotation in the affected shoulder

    Time frame: Baseline, Day 92

  6. Change From Baseline to Day 92 in Active Internal Rotation

    AROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder

    Time frame: Baseline, Day 92

  7. Change From Baseline to Day 92 in Passive Internal Rotation

    PROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder

    Time frame: Baseline, Day 92

  8. Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score

    Composite score ranging from 0-100, with 0 being worst pain and function loss, derived from the sum of the scores from pain subscale (11-point NRS where 0=no pain at all and 10=pain) and function subscale (activity questionnaire where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

    Time frame: Baseline, Day 92

  9. Change From Baseline to Day 92 in ASES Pain Subscale

    Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant assessment of pain in response to "How bad is the pain in your affected shoulder today?" on an 11-point numerical rating scale (NRS) where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

    Time frame: Baseline, Day 92

  10. Change From Baseline to Day 92 in ASES Function Subscale

    Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

    Time frame: Baseline, Day 92

  11. Subject Satisfaction With Treatment at Day 92

    Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.

    Time frame: Day 92

  12. Investigator Assessment of Improvement With Treatment at Day 92

    Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

    Time frame: Day 92

07

Results

Posted May 25, 2017

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Started1010101010
Completed1010101010
Not completed00000

Outcome measures

PrimaryChange From Baseline to Day 92 in Active Forward Flexion

Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Active Forward Flexion
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Active Forward Flexion22.9 ± 13.8337.5 ± 22.8942.9 ± 30.6423.8 ± 41.9712.0 ± 12.68
SecondaryChange From Baseline to Day 92 in Passive Forward Flexion

Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Passive Forward Flexion
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Passive Forward Flexion21.8 ± 11.9239.1 ± 22.1346.2 ± 20.3510.5 ± 23.9612.0 ± 14.13
SecondaryChange From Baseline to Day 92 in Active Abduction

AROM measurement using a goniometer to assess abduction in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Active Abduction
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Active Abduction28.4 ± 15.8136.0 ± 32.9453.7 ± 27.5935.8 ± 41.0216.7 ± 8.06
SecondaryChange From Baseline to Day 92 in Passive Abduction

PROM measurement using a goniometer to assess abduction in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Passive Abduction
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Passive Abduction28.6 ± 15.6944.8 ± 34.6956.1 ± 30.0518.0 ± 40.8724.3 ± 29.69
SecondaryChange From Baseline to Day 92 in Active External Rotation

AROM measurement using a goniometer to assess external rotation in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Active External Rotation
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Active External Rotation24.8 ± 13.3919.7 ± 27.4916.6 ± 16.797.4 ± 29.156.0 ± 27.87
SecondaryChange From Baseline to Day 92 in Passive External Rotation

PROM measurement using a goniometer to assess external rotation in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Passive External Rotation
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Passive External Rotation20.0 ± 9.6419.3 ± 24.5740.9 ± 33.719.1 ± 29.3210.7 ± 20.27
SecondaryChange From Baseline to Day 92 in Active Internal Rotation

AROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Active Internal Rotation
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Active Internal Rotation8.1 ± 14.1213.0 ± 20.859.5 ± 26.8717.4 ± 24.431.2 ± 20.92
SecondaryChange From Baseline to Day 92 in Passive Internal Rotation

PROM measurement using a goniometer to assess internal rotation with the elbow up to 90° abduction in the affected shoulder

Time frame:
Baseline, Day 92
Reported as:
Mean · degrees
Change From Baseline to Day 92 in Passive Internal Rotation
degreesAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in Passive Internal Rotation8.4 ± 16.8719.8 ± 21.7013.1 ± 23.3823.6 ± 18.772.9 ± 17.55
SecondaryChange From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score

Composite score ranging from 0-100, with 0 being worst pain and function loss, derived from the sum of the scores from pain subscale (11-point NRS where 0=no pain at all and 10=pain) and function subscale (activity questionnaire where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

Time frame:
Baseline, Day 92
Reported as:
Mean · units on a scale
Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score
units on a scaleAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score26.9 ± 13.1741.6 ± 18.9935.9 ± 24.3319.3 ± 24.299.9 ± 15.84
SecondaryChange From Baseline to Day 92 in ASES Pain Subscale

Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant assessment of pain in response to "How bad is the pain in your affected shoulder today?" on an 11-point numerical rating scale (NRS) where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

Time frame:
Baseline, Day 92
Reported as:
Mean · units on a scale
Change From Baseline to Day 92 in ASES Pain Subscale
units on a scaleAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in ASES Pain Subscale10.0 ± 11.0615.5 ± 13.2215.5 ± 14.998.0 ± 12.521.5 ± 11.32
SecondaryChange From Baseline to Day 92 in ASES Function Subscale

Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

Time frame:
Baseline, Day 92
Reported as:
Mean · units on a scale
Change From Baseline to Day 92 in ASES Function Subscale
units on a scaleAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Change From Baseline to Day 92 in ASES Function Subscale17.4 ± 8.7226.0 ± 10.9819.2 ± 12.3611.3 ± 13.538.4 ± 5.85
SecondarySubject Satisfaction With Treatment at Day 92

Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.

Time frame:
Day 92
Reported as:
Count of participants · Participants
Subject Satisfaction With Treatment at Day 92
ParticipantsAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Very satisfied46835
Quite satisfied42132
Neither satisfied nor dissatisfied21033
Quite dissatisfies01110
Very dissatisfied00000
SecondaryInvestigator Assessment of Improvement With Treatment at Day 92

Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

Time frame:
Day 92
Reported as:
Count of participants · Participants
Investigator Assessment of Improvement With Treatment at Day 92
ParticipantsAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Very much improved15732
Much improved32212
Minimally improved52153
No change10012
Minimally worse01001
Much worse00000
Very much worse00000

Adverse events

Collected over 129 days (up to 30 day screening period and 92±7 day study period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.29 mg/1 mL0/10 (0%)0/10 (0%)9/10 (90%)
AA4500 0.58 mg/2 mL0/10 (0%)0/10 (0%)9/10 (90%)
AA4500 0.58 mg/1 mL0/10 (0%)0/10 (0%)10/10 (100%)
AA4500 0.58 mg/0.5 mL0/10 (0%)0/10 (0%)10/10 (100%)
Shoulder Exercises Only0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Showing 10 of 56
Most frequent other events
EventAA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises Only
Injection site haematomaGeneral disorders4/104/103/106/100/10
Injection site painGeneral disorders6/106/106/104/100/10
Injection site swellingGeneral disorders2/103/102/105/100/10
Musculoskeletal painMusculoskeletal and connective tissue disorders2/101/104/102/102/10
Injection site haemorrhageGeneral disorders1/102/103/100/100/10
ContusionInjury, poisoning and procedural complications1/102/101/101/100/10
Pain in extremityMusculoskeletal and connective tissue disorders0/101/101/102/100/10
InsomniaPsychiatric disorders2/100/100/100/100/10
EcchymosisSkin and subcutaneous tissue disorders1/101/102/101/100/10
HypothyroidismEndocrine disorders1/100/100/100/100/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)AA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises OnlyTotal
Mean49.1 ± 4.9354.1 ± 8.8158.4 ± 8.9753.2 ± 5.7155.1 ± 7.0254.0 ± 7.60
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises OnlyTotal
Female8898740
Male2212310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises OnlyTotal
Hispanic or Latino200002
Not Hispanic or Latino81010101048
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises OnlyTotal
American Indian or Alaska Native000000
Asian001001
Native Hawaiian or Other Pacific Islander100001
Black or African American000000
White9109101048
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)AA4500 0.29 mg/1 mLAA4500 0.58 mg/2 mLAA4500 0.58 mg/1 mLAA4500 0.58 mg/0.5 mLShoulder Exercises OnlyTotal
United States101010101050
08

Study locations

15 sites
  • Alabama Orthopaedic Center - Research
    Birmingham, Alabama 35209, United States
  • HOPE Research Institute
    Phoenix, Arizona 85050, United States
  • Tucson Orthopaedic Institute
    Tucson, Arizona 85712, United States
  • OrthoArkansas
    Little Rock, Arkansas 72205, United States
  • CORE Orthopaedic Medical Center
    Encinitas, California 92024, United States
  • Triwest Research Associates
    La Mesa, California 91942, United States
  • Advent Clinical Research
    Pinellas Park, Florida 33781, United States
  • Rockford Orthopedic Associates
    Rockford, Illinois 61107, United States
  • The Indiana Hand to Shoulder Center
    Indianapolis, Indiana 46260, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • David R. Mandel, MD, Inc.
    Cleveland, Ohio 44143, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73109, United States
  • Blair Orthopedic Associates, Inc.
    Altoona, Pennsylvania 16602, United States
  • Alpha Clinical Research, LLC
    Clarksville, Tennessee 37043, United States
  • Basin Orthopedic Surgical Specialists
    Odessa, Texas 79761, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 4 years 3 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2011
First posted
Dec 2, 2011
Start
Nov 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results delay requested
Mar 17, 2015
Results first posted
May 25, 2017
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01483963
Responsible party
Sponsor
First posted
Dec 2, 2011
Start date
Nov 2011
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
May 25, 2017
Last update
Oct 5, 2017

Study contacts

Neil H Shusterman, MD FACP
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion